BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Smartwatches: Remain Associated and Dynamic - 2Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- 3Shah Capital pushes for Novavax sale, warns of proxy fight
- 4Russia accidentally destroys its only way of sending astronauts to space
- 54 Energy-Proficient Clothes washers to Consider in 2024
- Which Film Has the Incomparable Melodic Score?
- Israeli strike on Gaza City vehicle kills at least four, report says
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- The Most Vital Crossroads in Olympic History
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- Scientists discover black hole flare with the light of 10 trillion suns
- Pick Your Favored sort of cooking
